ClinicalTrials.gg
CompletedNCT03021499AURORAUpdated Mar 27, 2023Results posted

Aurinia Renal Response in Active Lupus With Voclosporin

A Phase 3 interventional study of Voclosporin and Placebo Oral Capsule in Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 187 sites in 31 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
7th of 100
358 · median 50
Started
2017
the only one that year
Phase 3
16 of 114
2 open now
Registered
38th of 114
by date
Lead sponsor
7 of 114
Aurinia Pharmaceuticals Inc.

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 7th largest by enrollment of the 100 interventional ones that give a count, is the only one that started in 2017, is one of 16 in phase 3, and was the 38th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.

Read the detailed description

The aim of the current study is to investigate whether voclosporin, added to the standard of care treatment in active lupus nephritis (LN), is able to reduce disease activity over a treatment period of 52 weeks. The background therapy will be mycophenolate mofetil (MMF) and initial treatment with IV methylprednisolone, followed by a reducing course of oral corticosteroids. Subjects with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria (as measured by Urine Protein Creatinine Ratio (UPCR)) while demonstrating an acceptable safety profile.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

Keywords

  • lupus nephritis
  • calcineurin inhibitors
  • voclosporin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects with evidence of active nephritis, defined as follows:
  • Kidney result within 2 years prior to screening indicating Class III, IV-S, IV-G (alone or in combination with Class V), or Class V LN with a doubling or greater increase of UPCR within the last 6 months to a minimum of ≥1.5 mg/mg for Class III/IV or to a minimum of ≥2 mg/mg for Class V at screening. Biopsy results over 6 months prior to screening must be reviewed with a medical monitor to confirm eligibility.

OR

  • Kidney biopsy result within 6 months prior to screening indicating Class III, IV-S or IV-G (alone or in combination with Class V) LN with a UPCR of ≥1.5 mg/mg at screening.

OR

  • Kidney biopsy result within 6 months prior to screening indicating Class V LN and a UPCR of ≥2 mg/mg at screening.

    • Women of must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.

Exclusion Criteria:

  • Estimated (eGFR) of ≤45 mL/minute at screening.
  • Current or medical history of:

    • Congenital or acquired immunodeficiency.
    • In the opinion of the Investigator, drug or alcohol abuse within 2 years prior to screening.
    • within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.
    • Lymphoproliferative disease or previous total lymphoid irradiation.
    • Severe viral infection or known infection.
    • Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
  • Other known clinically significant active medical conditions, such as:

    • Severe cardiovascular disease, liver dysfunction or or asthma requiring oral or any other overlapping condition for which the condition or the treatment of the condition may affect the study assessments or outcomes.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
358 participants (actual)

Study arms

  • Experimental
    Voclosporin

    oral, 23.7 mg twice daily (BID)

    Drug: Voclosporin

  • Placebo comparator
    Placebo Oral Capsule

    Voclosporin placebo, oral, 3 capsules twice daily (BID)

    Drug: Placebo Oral Capsule

Interventions

  • calcineurin inhibitor

    Also known as: ISA247

  • DrugPlacebo Oral Capsule

    matching placebo capsule

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adjudicated Renal Response at Week 52

    The primary efficacy endpoint was the number of subjects showing renal response at Week 52. Renal response was adjudicated based on blinded data by an independent Clinical Endpoints Committee based on meeting the following criteria * UPCR of ≤0.5 mg/mg \& * eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20% \& * Received no rescue medication for LN \& * Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during Weeks 44 through 52, prior to assessment Note:To be disqualified from renal response, the subject had to fail both eGFR measures (i.e., confirmed eGFR \<60 mL/min/1.73 m2 \& confirmed \>20% drop from baseline) \& have an associated treatment-related or disease-related AE that impacted eGFR Withdrawals prior to Week 52 with insufficient Week 52 data to determine response were defined non responders. Subjects who discontinued study drug but continued to attend study visits had their data assessed for response

    Time frame: 52 Weeks

Secondary outcomes

  1. Number of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less

    Number of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less

    Time frame: 52 Weeks

  2. Time to Urine Protein Creatinine Ratio of ≤0.5 mg/mg (Number of Days)

    Time in days to reduction in Urine Protein Creatinine Ratio to decrease to 0.5 mg/mg or less.

    Time frame: 52 Weeks

  3. Number of Participants With Renal Response at Week 24

    Number of subjects showing renal response at Week 24. Renal response was adjudicated based on blinded data by an Independent Clinical Endpoints Committee based on the following criteria: UPCR of ≤0.5 mg/mg, \& eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20%, and Received no rescue medication for LN \& Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during Weeks 16 through 24, just prior to the renal response assessment. Note:To be disqualified from renal response, the subject had to fail both eGFR measures (i.e., confirmed eGFR \<60 mL/min/1.73 m2 AND confirmed \>20% drop from BL) \& have an associated treatment-related or disease-related AE that impacted eGFR. Subjects who withdrew prior to the Week 24 assessment and provided insufficient Week 24 data to determine response were defined as non-responders. Subjects who discontinued study drug but continued to attend study visits had their data assessed for response.

    Time frame: Week 24

  4. Number of Subjects With Partial Renal Response at Weeks 24 & 52

    Number of subjects with partial Renal Response (defined as a 50% reduction in UPCR from baseline) at Week 24 and at Week 52. Baseline UPCR is the average of 2 pre-randomisation values.

    Time frame: Weeks 24 and 52

  5. Number of Subjects Achieving, and Remaining in, Renal Response (Urine Protein Creatinine Ratio ≤0.5 mg/mg)

    Number of subjects achieving, and remaining in, renal response (Urine Protein Creatinine ratio ≤0.5 mg/mg)

    Time frame: Week 52

  6. Duration of Renal Response (Number of Days)

    Duration in days until second occurrence of UPCR \>0.5 mg/mg in those subjects who achieve a reduction in UPCR to below 0.5 mg/mg

    Time frame: Week 52

  7. Number of Subjects Achieving 50% Reduction in Urine Protein Creatinine Ratio

    Number of subjects achieving 50% reduction in Urine Protein Creatinine ratio

    Time frame: 52 Weeks

  8. Time to 50% Reduction in UPCR (Number of Days)

    Time in days to reduction in Urine Protein Creatinine Ratio to decrease by 50% compared to baseline. Baseline is the average of two pre-randomisation values.

    Time frame: 52 weeks

  9. Change From Baseline in eGFR

    Change from baseline by visit in estimated Glomerular Filtration rate. eGFR is corrected to a maximum value of 90 mL/min/1.73 m2

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 16, 20, 24, 30, 36, 42, 48 and 52.

  10. Change From Baseline in UPCR

    Change from baseline by visit in Urine Protein Creatinine Ratio. Baseline is the average of two pre-randomisation values.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 16, 20, 24, 30, 36, 42, 48 and 52.

  11. Number of Subjects With Renal Response With Low Dose Steroids

    Programmed Renal Response whilst on low dose steroids (\<2.5 mg/day) for the preceding 8 Weeks at Weeks 24 and 52

    Time frame: Week 24 and Week 52

  12. Change From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA - SLEDAI)

    Change from baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at Week 24 and 52. The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.

    Time frame: Week 24 and Week 52

  13. Change From Baseline in Patient Reported Outcomes

    Health-related quality of life (HRQoL) information was collected using the Short Form Health Survey (SF-36) HRQoL assessment and the LupusPRO (v1.7) assessment. The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. Scoring ranges from 0 to 100 with higher scores reflecting better health. LupusPro assessment is a patient-reported questionnaire regarding the effect of lupus or its treatment on the patient's health, quality of life, and the medical care received related to lupus. The questionnaire consists of 43 questions within 8 HRQOL domains and 4 Non-HRQoL domains. Scores range from 0 to 100 with higher scores reflecting better quality of life.

    Time frame: Week 24 and Week 52

07

Results

Posted Jun 16, 2021

Participant flow

Eligible subjects were randomized in a ratio of 1:1 to receive either voclosporin 23.7 mg twice daily (BID) or matching placebo for 52 weeks. All subjects were also to receive 2 g/day mycophenolate mofetil (MMF). In addition, all subjects were to receive 0.5 g/day intravenous (IV) methylprednisolone on Days 1 and 2 before changing to a reducing course of oral corticosteroid therapy on Day 3.

Participant flow — Overall Study
MilestoneVoclosporinPlacebo
Started179178
Week 24167162
Week 52162147
Completed163147
Not completed1631
Withdrew: Adverse event10
Withdrew: Death15
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up13
Withdrew: Physician decision23
Withdrew: Pregnancy10
Withdrew: Withdrawal by subject714
Withdrew: Prohibited medication required10
Withdrew: Protocol non-compliance11
Withdrew: None of the above04
Withdrew: Adverse event (ae) prior to first dose10

Outcome measures

PrimaryNumber of Participants With Adjudicated Renal Response at Week 52

The primary efficacy endpoint was the number of subjects showing renal response at Week 52. Renal response was adjudicated based on blinded data by an independent Clinical Endpoints Committee based on meeting the following criteria * UPCR of ≤0.5 mg/mg \& * eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20% \& * Received no rescue medication for LN \& * Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during Weeks 44 through 52, prior to assessment Note:To be disqualified from renal response, the subject had to fail both eGFR measures (i.e., confirmed eGFR \<60 mL/min/1.73 m2 \& confirmed \>20% drop from baseline) \& have an associated treatment-related or disease-related AE that impacted eGFR Withdrawals prior to Week 52 with insufficient Week 52 data to determine response were defined non responders. Subjects who discontinued study drug but continued to attend study visits had their data assessed for response

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Adjudicated Renal Response at Week 52
ParticipantsVoclosporinPlacebo Oral Capsule
Number of renal responders7340
Number of renal non-responders106138
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.65 · 95% CI 1.64 to 4.27The model is based on a logistic regression with terms for treatment, baseline UPCR, biopsy class, MMF use at baseline and Region.
SecondaryNumber of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less

Number of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less
ParticipantsVoclosporinPlacebo Oral Capsule
Subjects with UPCR ≤ 0.511678
Subjects without UPCR ≤ 0.563100
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Log Rank · p = <0.001 · Hazard ratio (hr): 2.02 · 95% CI 1.51 to 2.7
SecondaryTime to Urine Protein Creatinine Ratio of ≤0.5 mg/mg (Number of Days)

Time in days to reduction in Urine Protein Creatinine Ratio to decrease to 0.5 mg/mg or less.

Time frame:
52 Weeks
Reported as:
Median · days
Time to Urine Protein Creatinine Ratio of ≤0.5 mg/mg (Number of Days)
daysVoclosporinPlacebo Oral Capsule
Time to Urine Protein Creatinine Ratio of ≤0.5 mg/mg (Number of Days)169 (141 to 214)372 (295 to NA)
SecondaryNumber of Participants With Renal Response at Week 24

Number of subjects showing renal response at Week 24. Renal response was adjudicated based on blinded data by an Independent Clinical Endpoints Committee based on the following criteria: UPCR of ≤0.5 mg/mg, \& eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20%, and Received no rescue medication for LN \& Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during Weeks 16 through 24, just prior to the renal response assessment. Note:To be disqualified from renal response, the subject had to fail both eGFR measures (i.e., confirmed eGFR \<60 mL/min/1.73 m2 AND confirmed \>20% drop from BL) \& have an associated treatment-related or disease-related AE that impacted eGFR. Subjects who withdrew prior to the Week 24 assessment and provided insufficient Week 24 data to determine response were defined as non-responders. Subjects who discontinued study drug but continued to attend study visits had their data assessed for response.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With Renal Response at Week 24
ParticipantsVoclosporinPlacebo Oral Capsule
Number of renal responders5835
Number of renal non-responders121143
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Regression, Cox · p = 0.002 · Odds ratio (or): 2.23 · 95% CI 1.34 to 3.72The hazard ratios are from a Cox's proportional hazards model with terms for treatment arm, baseline UPCR, biopsy class, MMF use at baseline and Region
SecondaryNumber of Subjects With Partial Renal Response at Weeks 24 & 52

Number of subjects with partial Renal Response (defined as a 50% reduction in UPCR from baseline) at Week 24 and at Week 52. Baseline UPCR is the average of 2 pre-randomisation values.

Time frame:
Weeks 24 and 52
Reported as:
Count of participants · Participants
Number of Subjects With Partial Renal Response at Weeks 24 & 52
ParticipantsVoclosporinPlacebo Oral Capsule
Week 2412689
Week 5212592
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = <0.001 (Week 24) · Odds ratio (or): 2.43 · 95% CI 1.56 to 3.79Week 24
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = <0.001 (Week 52) · Odds ratio (or): 2.26 · 95% CI 1.45 to 3.51Week 52
SecondaryNumber of Subjects Achieving, and Remaining in, Renal Response (Urine Protein Creatinine Ratio ≤0.5 mg/mg)

Number of subjects achieving, and remaining in, renal response (Urine Protein Creatinine ratio ≤0.5 mg/mg)

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Subjects Achieving, and Remaining in, Renal Response (Urine Protein Creatinine Ratio ≤0.5 mg/mg)
ParticipantsVoclosporinPlacebo Oral Capsule
Subjects achieving UPCR ≤ 0.5 mg/mg11678
number with 2nd occurrence of UPCR > 0.5 mg/mg5337
number without 2nd occurrence of UPCR > 0.5 mg/mg6341
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Regression, Cox · p = 0.349 · Hazard ratio (hr): 0.81 · 95% CI 0.53 to 1.25
  • Voclosporin vs Placebo Oral Capsule · Log Rank · p = 0.646
SecondaryDuration of Renal Response (Number of Days)

Duration in days until second occurrence of UPCR \>0.5 mg/mg in those subjects who achieve a reduction in UPCR to below 0.5 mg/mg

Time frame:
Week 52
Reported as:
Median · days
Duration of Renal Response (Number of Days)
daysVoclosporinPlacebo Oral Capsule
Duration of Renal Response (Number of Days)216 (127 to NA)198 (103 to NA)
SecondaryNumber of Subjects Achieving 50% Reduction in Urine Protein Creatinine Ratio

Number of subjects achieving 50% reduction in Urine Protein Creatinine ratio

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Number of Subjects Achieving 50% Reduction in Urine Protein Creatinine Ratio
ParticipantsVoclosporinPlacebo Oral Capsule
Subjects with 50% UPCR reduction173135
Subjects without 50% UPCR reduction643
SecondaryTime to 50% Reduction in UPCR (Number of Days)

Time in days to reduction in Urine Protein Creatinine Ratio to decrease by 50% compared to baseline. Baseline is the average of two pre-randomisation values.

Time frame:
52 weeks
Reported as:
Median · days
Time to 50% Reduction in UPCR (Number of Days)
daysVoclosporinPlacebo Oral Capsule
Time to 50% Reduction in UPCR (Number of Days)29 (29 to 32)63 (57 to 87)
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Log Rank · p = <0.001 · Hazard ratio (hr): 2.05 · 95% CI 1.62 to 2.6
SecondaryChange From Baseline in eGFR

Change from baseline by visit in estimated Glomerular Filtration rate. eGFR is corrected to a maximum value of 90 mL/min/1.73 m2

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 16, 20, 24, 30, 36, 42, 48 and 52.
Reported as:
Mean · ml/min/1.73 square metres
Change From Baseline in eGFR
ml/min/1.73 square metresVoclosporinPlacebo Oral Capsule
Baseline78.3 ± 15.8377.4 ± 16.98
Week 2 change from baseline-1.5 ± 9.443.3 ± 10.12
Week 4 change from baseline-0.4 ± 10.393.2 ± 9.86
Week 8 change from baseline-0.9 ± 13.13.8 ± 11.27
Week 12 change from baseline-0.3 ± 11.743.3 ± 12.85
Week 16 change from baseline-0.1 ± 12.272.8 ± 13.25
Week 20 change from baseline-0.7 ± 12.093.2 ± 13.04
Week 24 change from baseline-0.3 ± 13.82.8 ± 13.84
Week 30 change from baseline-0.8 ± 14.21.8 ± 14.4
Week 36 change from baseline-1.9 ± 14.891.5 ± 14.84
Week 42 change from baseline-2.8 ± 16.71.5 ± 15.53
Week 48 change from baseline-3.6 ± 17.21.1 ± 15.71
Week 52 change from baseline-1.5 ± 16.161.5 ± 15
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = < 0.001 · Mean difference (least squares): -4.6 · 95% CI -7.3 to -1.9
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.014 · Mean difference (least squares): -3.4 · 95% CI -6.1 to -0.7
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = < 0.001 · Mean difference (least squares): -4.6 · 95% CI -7.3 to -1.9
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.017 · Mean difference (least squares): -3.3 · 95% CI -6 to -0.6
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.085 · Mean difference (least squares): -2.4 · 95% CI -5.1 to 0.3
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.035 · Mean difference (least squares): -3 · 95% CI -5.7 to -0.2
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.121 · Mean difference (least squares): -2.2 · 95% CI -5 to 0.6
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.12 · Mean difference (least squares): -2.2 · 95% CI -5 to 0.6
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.102 · Mean difference (least squares): -2.3 · 95% CI -5.1 to 0.5
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.022 · Mean difference (least squares): -3.3 · 95% CI -6.1 to 0.5
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.004 · Mean difference (least squares): -4.1 · 95% CI -7 to -1.3
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.055 · Mean difference (least squares): -2.8 · 95% CI -5.7 to 0.1
SecondaryChange From Baseline in UPCR

Change from baseline by visit in Urine Protein Creatinine Ratio. Baseline is the average of two pre-randomisation values.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 16, 20, 24, 30, 36, 42, 48 and 52.
Reported as:
Mean · mg/mg
Change From Baseline in UPCR
mg/mgVoclosporinPlacebo Oral Capsule
Baseline4.14 ± 2.7113.87 ± 2.363
Week 2 change from baseline-1.46 ± 1.991-0.7 ± 2.312
Week 4 change from baseline-1.98 ± 2.29-1.07 ± 2.155
Week 8 change from baseline-2.23 ± 2.213-1.43 ± 2.448
Week 12 change from baseline-2.56 ± 2.293-1.48 ± 2.688
Week 16 change from baseline-2.75 ± 2.462-1.58 ± 2.81
Week 20 change from baseline-2.74 ± 2.968-1.54 ± 2.82
Week 24 change from baseline-2.74 ± 2.567-1.59 ± 2.899
Week 30 change from baseline-2.66 ± 3.336-1.7 ± 3.112
Week 36 change from baseline-2.74 ± 2.871-1.63 ± 3.188
Week 42 change from baseline-2.91 ± 2.522-1.78 ± 3.39
Week 48 change from baseline-2.71 ± 2.807-1.8 ± 3.004
Week 52 change from baseline-2.65 ± 2.872-1.88 ± 3.05
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.011 · Mean difference (least squares): -0.56 · 95% CI -1 to -0.13
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -0.76 · 95% CI -1.13 to -0.4
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -0.7 · 95% CI -1.05 to -0.34
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -0.94 · 95% CI -1.33 to -0.55
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -1.18 · 95% CI -1.6 to -0.76
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -1.16 · 95% CI -1.63 to -0.68
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -1.15 · 95% CI -1.59 to -0.72
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -1.02 · 95% CI -1.58 to -0.46
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -1.21 · 95% CI -1.73 to -0.69
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -1.37 · 95% CI -1.87 to -0.86
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -1.06 · 95% CI -1.56 to -0.55
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = <0.001 · Mean difference (least squares): -0.99 · 95% CI -1.52 to -0.46
SecondaryNumber of Subjects With Renal Response With Low Dose Steroids

Programmed Renal Response whilst on low dose steroids (\<2.5 mg/day) for the preceding 8 Weeks at Weeks 24 and 52

Time frame:
Week 24 and Week 52
Reported as:
Count of participants · Participants
Number of Subjects With Renal Response With Low Dose Steroids
ParticipantsVoclosporinPlacebo Oral Capsule
Renal Response at Week 243216
Renal Response at Week 526436
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = 0.008 (Week 24) · Odds ratio (or): 2.44 · 95% CI 1.26 to 4.71Week 24
  • Voclosporin vs Placebo Oral Capsule · Regression, Logistic · p = <0.001 (Week 52) · Odds ratio (or): 2.44 · 95% CI 1.48 to 4.00Week 52
SecondaryChange From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA - SLEDAI)

Change from baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at Week 24 and 52. The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA - SLEDAI)
scores on a scaleVoclosporinPlacebo Oral Capsule
Change from baseline at Week 24-4.5 (-5.4 to -3.7)-4.1 (-5.0 to -3.2)
Change from baseline at Week 52-6 (-6.7 to -5.2)-5.5 (-6.3 to -4.7)
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.373 (Week 24) · Least squares mean difference: -0.5 · 95% CI -1.6 to 0.6Week 24
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.277 (Week 52) · Least squares mean difference: -0.5 · 95% CI -1.4 to 0.4Week 52
SecondaryChange From Baseline in Patient Reported Outcomes

Health-related quality of life (HRQoL) information was collected using the Short Form Health Survey (SF-36) HRQoL assessment and the LupusPRO (v1.7) assessment. The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. Scoring ranges from 0 to 100 with higher scores reflecting better health. LupusPro assessment is a patient-reported questionnaire regarding the effect of lupus or its treatment on the patient's health, quality of life, and the medical care received related to lupus. The questionnaire consists of 43 questions within 8 HRQOL domains and 4 Non-HRQoL domains. Scores range from 0 to 100 with higher scores reflecting better quality of life.

Time frame:
Week 24 and Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Patient Reported Outcomes
score on a scaleVoclosporinPlacebo Oral Capsule
SF-36 change from baseline at Week 246.64 (4.34 to 8.93)7.11 (4.80 to 9.42)
SF-36 change from baseline at Week 5210.44 (8.04 to 12.83)10.81 (8.37 to 13.25)
LupusPRO HRQOL change from baseline at Week 247.7 (5.40 to 10.13)6.06 (3.68 to 8.45)
LupusPRO HRQOL change from baseline at Week 529.24 (6.78 to 11.70)9.84 (7.33 to 12.35)
LupusPRO non-HRQOL change from baseline at Week 241.06 (-1.32 to 3.44)2.94 (0.54 to 5.35)
LupusPRO non-HRQOL change from baseline at Week 524.08 (1.60 to 6.56)3.74 (1.22 to 6.26)
Statistical analysis
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.733 · Slope: -0.47 · 95% CI -3.21 to 2.26
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.801 · Mean difference (least squares): -0.37 · 95% CI -3.29 to 2.54
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.239 · Mean difference (least squares): 1.7 · 95% CI -1.14 to 4.54
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.695 · Mean difference (least squares): -0.6 · 95% CI -3.62 to 2.42
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.19 · Mean difference (least squares): -1.89 · 95% CI -4.72 to 0.94
  • Voclosporin vs Placebo Oral Capsule · Mixed Models Analysis · p = 0.826 · Mean difference (least squares): 0.826 · 95% CI -2.67 to 3.35

Adverse events

Collected over Reporting period is from first dose up to 30 days following last dose (Week 52).. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voclosporin1/178 (0.6%)37/178 (20.8%)161/178 (90.4%)
Placebo Oral Capsule5/178 (2.8%)38/178 (21.3%)156/178 (87.6%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventVoclosporinPlacebo Oral Capsule
PneumoniaInfections and infestations7/1788/178
Acute kidney injuryRenal and urinary disorders4/1782/178
Lupus nephritisRenal and urinary disorders1/1784/178
GastroenteritisInfections and infestations3/1780/178
BronchitisInfections and infestations0/1783/178
AnaemiaBlood and lymphatic system disorders3/1780/178
HypertensionVascular disorders3/1781/178
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders3/1783/178
Urinary tract infectionInfections and infestations2/1781/178
Renal impairmentRenal and urinary disorders2/1781/178
Most frequent other events
Showing 10 of 26
Most frequent other events
EventVoclosporinPlacebo Oral Capsule
Glomerular filtration rate decreasedInvestigations43/17815/178
HypertensionVascular disorders35/17814/178
DiarrhoeaGastrointestinal disorders34/17821/178
Upper respiratory tract infectionInfections and infestations31/17826/178
HeadacheNervous system disorders29/17811/178
Viral upper respiratory tract infectionInfections and infestations20/17818/178
AnaemiaBlood and lymphatic system disorders18/17810/178
Urinary tract infectionInfections and infestations17/17813/178
NauseaGastrointestinal disorders10/17817/178
ArthralgiaMusculoskeletal and connective tissue disorders8/17817/178

Baseline characteristics

Intent-to-Treat is comprised of all subjects who were randomized treatment, and was used for analysis of all Outcome Measures. Safety population comprised all randomized subjects who took at least one dose of study treatment, and was used for AE and SAE reporting. 1 Voclosporin subject was withdrawn due to an adverse event (AE) prior to receiving the first dose of Voclosporin.

Age, Continuous
Age, Continuous(years)VoclosporinPlaceboTotal
Mean32.8 ± 10.9333.6 ± 1133.2 ± 10.96
Sex: Female, Male
Sex: Female, Male(Participants)VoclosporinPlaceboTotal
Female161152313
Male182644
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VoclosporinPlaceboTotal
Hispanic or Latino5759116
Not Hispanic or Latino122118240
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VoclosporinPlaceboTotal
American Indian or Alaska Native044
Asian5356109
Native Hawaiian or Other Pacific Islander000
Black or African American211334
White6861129
More than one race374481
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)VoclosporinPlaceboTotal
United States262652
Southeast Asia5252104
Europe5252104
South America494897
Lupus Nephritis (LN) history
Lupus Nephritis (LN) history(years)VoclosporinPlaceboTotal
Years since diagnosis of systemic lupus erythematosus (SLE)6.6 ± 6.416.9 ± 6.076.7 ± 6.23
Years since diagnosis of LN4.6 ± 5.074.7 ± 4.894.6 ± 4.97
Years since first Proteinuria4.8 ± 5.24.6 ± 4.514.7 ± 4.86
Baseline Urine Protein Creatinine Ratio (UPCR)
Baseline Urine Protein Creatinine Ratio (UPCR)(mg/mg)VoclosporinPlaceboTotal
Median4.14 ± 2.7113.87 ± 2.3634.00 ± 2.537
Baseline estimated glomerular filtration rate (eGFR)
Baseline estimated glomerular filtration rate (eGFR)(mL/min/1.73 m2)VoclosporinPlaceboTotal
Median92.1 ± 30.0690.4 ± 28.9791.2 ± 29.51
08

Study locations

187 sites
  • AURORA Investigative Center
    Huntsville, Alabama 35805, United States
  • AURORA Investigative Center
    Phoenix, Arizona 85032, United States
  • AURORA Investigative Center
    Phoenix, Arizona 85037, United States
  • AURORA Investigative Center
    Beverly Hills, California 90211, United States
  • AURORA Investigative Center
    Los Angeles, California 90022, United States
  • AURORA Investigative Center
    Los Angeles, California 90024, United States
  • AURORA Investigative Center
    Palo Alto, California 94305, United States
  • AURORA Investigative Center
    Thousand Oaks, California 91360, United States
  • AURORA Investigative Center
    Torrance, California 90502, United States
  • AURORA Investigative Center
    Aurora, Colorado 80045, United States
  • AURORA Investigative Center
    Denver, Colorado 80218, United States
  • AURORA Investigative Center
    New Haven, Connecticut 06510, United States
  • AURORA Investigative Center
    Clearwater, Florida 33765, United States
  • AURORA Investigative Center
    DeBary, Florida 32713, United States
  • AURORA Investigative Center
    Fort Lauderdale, Florida 33309, United States
  • AURORA Investigative Center
    Fort Myers, Florida 33901, United States
  • AURORA Investigative Center
    Miami, Florida 33125, United States
  • AURORA Investigative Center
    Orlando, Florida 32810, United States
  • AURORA Investigative Center
    Winter Park, Florida 32789, United States
  • AURORA Investigative Center
    Atlanta, Georgia 30318, United States
  • AURORA Investigative Center
    Columbus, Georgia 31904, United States
  • AURORA Investigative Center
    Lawrenceville, Georgia 30046, United States
  • AURORA Investigative Center
    Chicago, Illinois 60637, United States
  • AURORA Investigative Center
    Louisville, Kentucky 40202, United States
  • AURORA Investigative Center
    Baton Rouge, Louisiana 70809, United States
  • AURORA Investigative Center
    New Orleans, Louisiana 70121, United States
  • AURORA Investigative Center
    Boston, Massachusetts 02118, United States
  • AURORA Investigative Center
    Detroit, Michigan 48201-2017, United States
  • AURORA Investigative Center
    Grand Blanc, Michigan 48439, United States
  • AURORA Investigative Center
    Rochester, Minnesota 55905, United States
  • AURORA Investigative Center
    Saint Louis, Missouri 63110, United States
  • AURORA Investigative Center
    Las Vegas, Nevada 89128, United States
  • AURORA Investigative Center
    Newark, New Jersey 07103, United States
  • AURORA Investigative Center
    Great Neck, New York 11021, United States
  • AURORA Investigative Center
    New York, New York 10016, United States
  • AURORA Investigative Center
    New York, New York 10021-4823, United States
  • AURORA Investigative Center
    New York, New York 11203, United States
  • AURORA Investigative Center
    Syracuse, New York 13210, United States
  • AURORA Investigative Center
    Chapel Hill, North Carolina 27514, United States
  • AURORA Investigative Center
    Charlotte, North Carolina 28204, United States
  • AURORA Investigative Center
    Charlotte, North Carolina 28210, United States
  • AURORA Investigative Center
    Greenville, North Carolina 27834, United States
  • AURORA Investigative Center
    New Bern, North Carolina 28562, United States
  • AURORA Investigative Center
    Cleveland, Ohio 44109, United States
  • AURORA Investigative Center
    Columbus, Ohio 43210, United States
  • AURORA Investigative Center
    Oklahoma City, Oklahoma 73103, United States
  • AURORA Investigative Center
    Oklahoma City, Oklahoma 73104, United States
  • AURORA Investigative Center
    Charleston, South Carolina 29425, United States
  • AURORA Investigative Center
    Chattanooga, Tennessee 37408, United States
  • AURORA Investigative Center
    Hendersonville, Tennessee 37075, United States
  • AURORA Investigative Center
    Beaumont, Texas 77036, United States
  • AURORA Investigative Center
    Dallas, Texas 75231, United States
  • AURORA Investigative Center
    Dallas, Texas 75246, United States
  • AURORA Investigative Center
    Dallas, Texas 75390, United States
  • AURORA Investigative Center
    El Paso, Texas 79905, United States
  • AURORA Investigative Center
    El Paso, Texas 79935, United States
  • AURORA Investigative Center
    Houston, Texas 77030, United States
  • AURORA Investigative Center
    Arlington, Virginia 22205, United States
  • AURORA
    Richmond, Virginia 23298, United States
  • AURORA Investigative Center
    Buenos Aires, Argentina
  • AURORA Investigative Center
    Caba, Argentina
  • AURORA Investigative Center
    Córdoba, Argentina
  • AURORA Investigative Center
    La Plata, Argentina
  • AURORA Investigative Center
    San Miguel De Tucumán, Argentina
  • AURORA Investigative Cener
    Minsk, 220116, Belarus
  • AURORA Investigative Center
    Minsk, 223040, Belarus
  • AURORA Investigative Center
    Vitebsk, Belarus
  • AURORA Investigative Center
    Curitiba, Brazil
  • AURORA Investigative Center
    Porto Alegre, Brazil
  • AURORA Investigative Center
    Salvador, Brazil
  • AURORA Investigative Center
    São Paulo, Brazil
  • AURORA Investigative Center
    Plovdiv, Bulgaria
  • AURORA Investigative Center
    Smolyan, Bulgaria
  • AURORA Investigative Center
    Sofia, Bulgaria
  • AURORA Investigative Center
    Stara Zagora, 6001, Bulgaria
  • AURORA Investigative Center
    Vidin, Bulgaria
  • AURORA Investigative Center
    Edmonton, Alberta, Canada
  • AURORA Investigative Center
    Montreal, Quebec, Canada
  • AURORA Investigative Center
    Montréal, Quebec, Canada
  • AURORA Investigative Center
    Toronto, Canada
  • AURORA Investigative Center
    Santiago, Chile
  • AURORA Investigative Center
    Temuco, Chile
  • AURORA Investigative Center
    Valdivia, Chile
  • AURORA Investigative Center
    Barranquilla, Colombia
  • AURORA Investigative Center
    Bogotá, Colombia
  • AURORA Investigative Center
    Bucaramanga, Colombia
  • AURORA Investigative Center
    Zipaquirá, Colombia
  • AURORA Investigative Center
    San José, 10108, Costa Rica
  • AURORA Investigative Center
    San José, Costa Rica
  • AURORA Investigative Center
    Osijek, Croatia
  • AURORA Investigative Center
    Zagreb, Croatia
  • AURORA Investigative Center
    Santiago de los Caballeros, Dominican Republic
  • AURORA Investigative Center
    Santo Domingo, Dominican Republic
  • AURORA Investigative Center
    Guatemala City, Guatemala
  • AURORA Investigative Center
    Kita, Osaka, Japan
  • AURORA Investigative Center
    Chiba, Japan
  • AURORA Investigative Center
    Hiroshima, Japan
  • AURORA Investigative Center
    Ishikawa, Japan
  • AURORA Investigative Center
    Kitakyushu, Japan
  • AURORA Investigative Center
    Kita, Japan

Showing the first 100 of 187 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, Hooi LS, Brunetta P, Maciuca R, Solomons N. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013 Jan;8(1):147-53. doi: 10.2215/CJN.03290412. Epub 2012 Aug 9. PubMed 22879439 ↗
  • Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309. PubMed 24330024 ↗
  • Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013 Dec;53(12):1303-12. doi: 10.1002/jcph.166. Epub 2013 Oct 8. PubMed 23996158 ↗
  • Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. J Clin Pharmacol. 2013 Aug;53(8):819-26. doi: 10.1002/jcph.114. Epub 2013 Jun 4. PubMed 23736966 ↗
  • Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460. PubMed 22087680 ↗
  • Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22. PubMed 21943027 ↗
  • Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7. Erratum In: Lancet. 2021 May 29;397(10289):2048. doi: 10.1016/S0140-6736(21)01160-0. PubMed 33971155 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Sep 2019, 28 months.

Results were first posted in Jun 2021, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2017
First posted
Jan 16, 2017
StartActual
May 17, 2017
Primary completionActual
Sep 24, 2019
CompletionActual
Oct 10, 2019
Results first posted
Jun 16, 2021
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03021499
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Jan 16, 2017
Start date
May 17, 2017
Primary completion
Sep 24, 2019
Completion
Oct 10, 2019
Results posted
Jun 16, 2021
Last update
Mar 27, 2023

Study contacts

Samir Parikh, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion